GT Biopharma, Inc. is a clinical stage immuno-oncology company that develops novel therapies for cancer treatment using its proprietary NK cell engager (TriKE®) technology. This technology creates targeted immunotherapeutic agents that engage natural killer (NK) cells to selectively destroy cancer cells. The company focuses on treating various cancers, including acute lymphocytic leukemia, non-Hodgkin's lymphoma, acute myeloid leukemia, and multiple solid tumors.
- Website
- www.gtbiopharma.com
- Issuer profile
- All listings